Marjan Naraghi Arani, DO
Family Medicine · San Ramon, CANPI 1821187881
Payments from drug & device makers
Across 115 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$349
- Amgen$305
- Biohaven Pharmaceuticals, Inc.$294
- GSK$222
- Boehringer Ingelheim$212
- Lilly USA, LLC$129
- plus $942 from 20 others
What the payments were for
- Food & beverage$2,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $349 |
| Amgen | 12 | $305 |
| Biohaven Pharmaceuticals, Inc. | 11 | $294 |
| GSK | 5 | $222 |
| Boehringer Ingelheim | 13 | $212 |
| Lilly USA, LLC | 6 | $129 |
| Merck | 6 | $127 |
| Novo Nordisk | 6 | $96 |
| Exact Sciences | 3 | $88 |
| Kaleo, Inc. | 3 | $74 |
| AstraZeneca(2 entities) | 3 | $67 |
| Astellas Pharma US Inc | 3 | $64 |
| Bausch Health US, LLC | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Hologic Sales And Service, LLC | 2 | $44 |
| AbbVie(2 entities) | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $39 |
| Phadia US Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Gilead | 1 | $18 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$120
- NURTEC ODT$111
How this compares
$2,453 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $36,519 |
| EliquisApixaban | 45 | $32,394 |
| OzempicSemaglutide | 27 | $29,031 |
| LumiganBimatoprost | 12 | $3,951 |
| Rosuvastatin Calcium | 178 | $2,905 |
| Carbamazepine | 12 | $2,344 |
| SynthroidLevothyroxine Sodium | 26 | $2,241 |
| Levothyroxine Sodium | 176 | $1,974 |
| Estradiol | 14 | $1,736 |
| Atorvastatin Calcium | 185 | $1,234 |
| Amlodipine Besylate | 140 | $1,183 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $1,123 |
| Metoprolol Succinate | 66 | $1,098 |
| Potassium Chloride | 25 | $798 |
| Losartan Potassium | 74 | $797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $212 | $36,51926 claims |
| PfizerEliquis | $349 | $32,39445 claims |
| Novo NordiskOzempic | $96 | $29,03127 claims |
| AbbVieLumigan, Synthroid | $40 | $6,19238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in San Ramon
- Alfred TanSan Ramon$4.7M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.